AstraZeneca and Daiichi Sankyo’s Enhertu shows promise in breast cancer trial

AstraZeneca and Daiichi Sankyo have announced that their therapy Enhertu has shown a statistically and clinically meaningful progression-free survival (PFS) improvement in patients with HR-positive, HER2-low metastatic breast cancer.